FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Takedown
The FDA announced steps to restrict compounded GLP-1 products, specifically naming Hims & Hers. Novo Nordisk has also sued Hims & Hers over compounded semaglutide.
#hims and hers
3 stories
Hims & Hers Stock Retreats as Peptide Market Optimism Fades on Regulatory Uncertainty
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.
Endpoints News: The Peptide Fad Lures Noom, Hims & Hers and Health Tech Companies
Digital health companies are betting on peptides as the next big wellness category. They're banking on HHS Secretary RFK Jr. getting the FDA to lift restrictions on certain peptides.